MANAGEMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN RHEUMATOID ARTHRITIS: THE EXAMPLE OF THE "RIC NORD DE FRANCE" COHORT

J. Corli1, G. Baudens2, R. M. Filpo1, B. Cortel1, on behalf of RIC-Nord de France.

1Rheumatology, CHRU Lille, Lille; 2Rheumatology, Valenciennes, Valenciennes, France

Background: Glucocorticoid-induced osteoporosis (GIOP) is the most common cause of secondary osteoporosis. Patients followed for Rheumatoid Arthritis (RA) are particularly exposed to OP and have a greater risk of fracture, which must be prevented. The newest French guidelines for GIOP management were published in 2014 and it is not known yet how they are applied in real life.

Objectives: The objective of our study was to investigate the treatment of glucocorticoid-induced osteoporosis in the Rhumatisme Inflammatoires Chroniques — Nord de France (formerly known as RIC-NPC) network in 2016 for patients with rheumatoid arthritis (RA).

Methods: In this observational study, the patients studied were followed in the RIC network for RA from 2004 until June 2016, had at least one bone mineral density (BMD) assessment and glucocorticoid therapy during follow-up. Demographic characteristics of patients, BMD results, fractures and treatments implemented were collected from network data completed during consultations by practitioners.

Results: 647 patients were enrolled, including 511 women (79%). The average age of patients was 65.5 years (SD=12) with a mean DAS28 of 3.91 (SD=1.44), mean dose of steroid of 7.6 mg (SD=6.6) and a mean duration of treatment of 49 months (SD=53.7). The average T-score at the first BMD assessment was –0.99 at the spine and –1.03 at the total hip. 298 patients received an anti-osteoporotic treatment (46%). Treated patients were older (p<0.0001), with lower weight (p=0.0001) and had a lower T-score at both the spine and the total hip (p<0.0001 for both sites). They most often underwent a prior fracture (p<0.0001), and an initial T-score less than –1.5 SD (p<0.0001).

Conclusions: Our study has the advantage of reflecting the management of GIOP in a "real life" cohort. Almost half of our patients followed for RA who received corticosteroids had received treatment. According to French guidelines, the number of patients requiring an anti-osteoporotic treatment should be higher.

REFERENCES:

Disclosure of Interest: J. Corli Grant/research support from: Amgen, G. Baudens Grant/research support from: Amgen, R.-M. Filpo: None declared, B. Cortel Grant/research support from: Amgen


DIFFERENCES IN BONE METABOLISM BETWEEN INTERMITTENT AND CONTINUOUS TREATMENT WITH LHRR AGONISTS IN PROSTATE CANCER PATIENTS

K. R. Arevalo1, J. Iovra1, C. Vera1, E. Grau1, I. Chalmeta1, L. Gonzalez1, R. Negueruel1, C. Alcaliz1, I. Canovas1, C. Feced1, J. J. Frago1, R. Gonzalez1, E. Labrador1, I. Martinez1, C. Najera1, J. E. Olle1, F. M. Ortiz1, E. Vicente1, M. de la Rubia1, D. Hervas1, J. A. Roman1, 1Rheumatology Department, 2Urology Department, HUP La Fe, Biostatistical Unit, IIS La Fe, Valencia, Spain

Background: Prostate cancer is a hormone dependent neoplasia, therefore androgenic inhibition by LHRR agonists is the mainstay of treatment. There are different treatment regimen options: continuous or intermittent in order to decrease side effects. As for the bone effects, therapy with LHRR agonists increases bone resorption and decreases bone mineral density (BMD) all together increasing the risk of fracture. The influence of the different treatment regimen in bone metabolism has not been studied enough.

Objectives: To evaluate the effect of the LHRR agonists therapy different regimens on bone metabolism in prostate cancer patients, and whether antiresorptive treatment influences the evolution of BMD according to LHRR agonists treatment regimen.

Methods: We recruited patients from the Prostate Cancer Protocol of Osteoporotic Risk Assessment in our institution. The patients were evaluated in a basal visit (month 0) and 6–12–18–24 months after basal evaluation. Data of bone metabolism biomarkers, BMD values, LHRR agonists regimen and antiresorptive treatment was collected. Biostatistical analysis with software R was performed.

Results: We reviewed 69 patients and 52 prostate cancer patients without bone metastasis with 12 months follow up were selected. The mean age at diagnosis was 68.92 (8.44) years old, with a mean Gleason score of 7.1. 81% of patients had LHRR agonists active treatment, 81% of them were under continuous treatment scheme. 39% of patients initiated antiresorptive therapy, 24% with intermittent LHRR agonists and 76% with continuous LHRR agonists. At the basal evaluation 12% of patients had osteoporosis and the 32% had osteopenia. 43% of patients displayed vDT values under 20 ng/mL. Antiresorptive treatment influenced lumbar spine, femoral neck and hip BMD values (p<0.001). In patients with antiresorptive treatment, LHRR agonists intermittent scheme did not have an independent effect in any locations of BMD. In patients without antiresorptive therapy, intermittent LHRR agonists regimen have a positive effect on BMD in total hip and lumbar spine increasing their values compared to those on continuous LHRR agonists regimen. The effect in lumbar spine depends on the time of the intermittency. LHRR agonist intermittent therapy showed no significant influence on T score values of femoral neck, this effect was independent of antiresorptive therapy. In patients without antiresorptive treatment elevated beta-CTX levels were related to a decrease of BMD values (p<0.017).

No fractures were reported during the follow up period.

Conclusions: In our patients there is a high prevalence of vDT deficiency. Antiresorptive therapy had a positive effect in the BMD on both LHRR agonists treatment schemes. Patients without antiresorptive treatment under an intermittent LHRR agonists scheme display a better evolution in BMD values compared to those under a continuous scheme. In patients without antiresorptive treatment the evolution of BMD values was related to beta-CTX levels during follow up.

Disclosure of Interest: None declared


USEFULNESS OF DOPPLER ULTRASOUND EXAMINATIONS FOR DETECTING DEEP VENOUS THROMBOSIS DURING THE PERIOPERATIVE PERIOD IN PATIENTS WITH OSTEOPOROTIC FRACTURES OF THE PROXIMAL FEMUR

K. Nakaseko, N. Mayumi. Department of Orthopaedic Surgery and Rheumatology, KUWANA CITY MEDICAL CENTER, Kuwana Mie, Japan

Background: Deep venous thrombosis (DVT) can lead to a venous thromboembolism and increase the risk of a pulmonary thromboembolism (PE). PE is one of the most common causes of death in hospitalised surgical patients. Although there have been some prospective studies regarding the prevalence of DVT in patients with osteoporotic fractures of the proximal femur, based on the results of examinations involving three consecutive ultrasound scans. In addition, the usefulness of the d-dimer level as a predictor of DVT was investigated.

Objectives: This study was a single-centre prospective study. One hundred-five patients (18 males and 87 females) between the ages of 46 and 97 years with osteoporotic fractures of the proximal femur were enrolled. All patients were asymptomatic in terms of their clinical DVT findings.

Methods: Three Doppler ultrasound examinations of the lower extremities were conducted in each case: on admission, one day before surgery, and one week after surgery. The period from admission to surgery ranged from 2 to 8 days (mean: 5.4 days). The d-dimer level was measured at one week after surgery and its relationship with the presence/absence of DVT was evaluated by calculating sensitivity, specificity, positive predictive, and negative predictive values.

Results: DVT was detected in 20 patients (2 patients on admission, 9 patients one day before surgery, and 9 patients one week after surgery). The overall prevalence of DVT in the perioperative period was 19.0% (20/105). As for the characteristics of the patients that did and did not develop DVT, there were no significant differences between the two groups. When the d-dimer cut-off level was set at 0.5 µg/mL, the sensitivity and negative predictive value reached 100%, while the specificity was 16.5%, and the positive predictive value was 22.0%. A receiver operating characteristic (ROC) curve was drawn, and the optimal d-dimer cut-off level was examined. The ROC curve was closest to the upper left corner when the d-dimer cut-off level was 12.2 µg/mL. At that point, the sensitivity, specificity, positive predictive value, and negative predictive value were 55.0%, 69.4%, 28.9%, and 86.8%, respectively.
Conclusions: In this prospective study, DVT was detected in 2 patients on admission, 9 patients one day before surgery, and 9 patients one week after surgery. As DVT can occur at any moment, performing repeated Doppler ultrasound examinations in the perioperative period is useful for quickly detecting DVT, which can cause PE. As for the d-dimer level, its sensitivity and negative predictive value reached 100% at a cut-off level of 4.3 μg/ml. Therefore, d-dimer assays could be a useful screening tool for DVT and might be a suitable substitute for Doppler ultrasound examinations.

Disclosure of Interest: None declared
DOI: 10.1136/annrheumdis-2018-eular.1314

Abstract AB1004 – Figure 1

Conclusions: One third of at-risk patients in this sub-cohort are not screened for osteoporosis. More patients are currently screened for osteoporosis by their rheumatologist than their GPs. Underscreening and treatment of osteoporosis in this clinic could be addressed by clearer GP–rheumatologist shared treatment model.

REFERENCES:

Disclosure of Interest: None declared

Abstract AB1005 – Figure 1

Conclusions: Osteoporosis screening is important in autoimmune conditions. One third of at-risk patients in this sub-cohort are not screened for osteoporosis. More patients are currently screened for osteoporosis by their rheumatologist than their GPs. Underscreening and treatment of osteoporosis in this clinic could be addressed by clearer GP-rheumatologist shared treatment model.

REFERENCES:

Disclosure of Interest: None declared